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Abstract
Background: In patients with genotype 1 chronic hepatitis C infection, telaprevir (TVR) in combination with peginterferon
and ribavirin (PR) significantly increased sustained virologic response (SVR) rates compared with PR alone. However,
genotypic changes could be observed in TVR-treated patients who did not achieve an SVR.
Methods: Population sequence analysis of the NS3N4A region was performed in patients who did not achieve SVR with TVR-
based treatment.
Results: Resistant variants were observed after treatment with a telaprevir-based regimen in 12% of treatment-naı ¨ve
patients (ADVANCE; T12PR arm), 6% of prior relapsers, 24% of prior partial responders, and 51% of prior null responder
patients (REALIZE, T12PR48 arms). NS3 protease variants V36M, R155K, and V36M+R155K emerged frequently in patients
with genotype 1a and V36A, T54A, and A156S/T in patients with genotype 1b. Lower-level resistance to telaprevir was
conferred by V36A/M, T54A/S, R155K/T, and A156S variants; and higher-level resistance to telaprevir was conferred by
A156T and V36M+R155K variants. Virologic failure during telaprevir treatment was more common in patients with genotype
1a and in prior PR nonresponder patients and was associated with higher-level telaprevir-resistant variants. Relapse was
usually associated with wild-type or lower-level resistant variants. After treatment, viral populations were wild-type with a
median time of 10 months for genotype 1a and 3 weeks for genotype 1b patients.
Conclusions: A consistent, subtype-dependent resistance profile was observed in patients who did not achieve an SVR with
telaprevir-based treatment. The primary role of TVR is to inhibit wild-type virus and variants with lower-levels of resistance
to telaprevir. The complementary role of PR is to clear any remaining telaprevir-resistant variants, especially higher-level
telaprevir-resistant variants. Resistant variants are detectable in most patients who fail to achieve SVR, but their levels
decline over time after treatment.
Citation: Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, et al. (2012) Hepatitis C Viral Evolution in Genotype 1 Treatment-Naı ¨ve and Treatment-
Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials. PLoS ONE 7(4): e34372. doi:10.1371/journal.pone.0034372
Editor: John E. Tavis, Saint Louis University, United States of America
Received February 14, 2012; Accepted March 1, 2012; Published April 12, 2012
Copyright:  2012 Kieffer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by Vertex Pharmaceuticals Incorporated (www.vrtx.com) and Janssen Pharmaceuticals, Inc. (http://www.
janssenpharmaceuticalsinc.com/). No other funding sources were used.
Competing Interests: The authors have read the journal’s policy and have the following conflicts: TLK, DJB, JCS, EZZ, AT, JS, JD, MJ, RSK, NA, and ADK are
employees and stock owners of Vertex Pharmaceuticals Incorporated. BA was an employee of Vertex Pharmaceuticals at the time this research was performed, is a
current Vertex stock owner, and is a current employee of Merrimack Pharmaceuticals. SDM, ID, AG, MB, and GP are employees of Janssen Pharmaceuticals and
stock owners of Johnson & Johnson. IMJ has received consulting and lecture fees from Abbott, Anadys Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers
Squibb, Gilead Sciences, GlobeImmune, Human Genome Sciences, Novartis, Pharmasset, Pfizer, Roche/Genentech, Sanofi-Aventis, Schering-Plough/Merck,
Tibotec, Vertex Pharmaceuticals Incorporated, and ZymoGenetics; and grant/research support from Anadys Pharmaceuticals, Boehringer Ingelheim, Gilead
Sciences, GlobeImmune, Human Genome Sciences, Novartis, Pharmasset, Roche/Genentech, Schering-Plough/Merck, Tibotec, and Vertex Pharmaceuticals
Incorporated. KES has received grant/research support from Anadys Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead, Merck,
Pharmasset, Schering-Plough and Vertex Pharmaceuticals; and is an Advisory or Review Committee Member for Bristol-Myers Squibb, Merck, Pfizer, Fibrogen,
Genentech, Tibotec, and Vertex Pharmaceuticals. SZ has received consulting/lecture fees from Abbott, Achillion, Anadys Pharmaceuticals, Bayer, Bristol-Myers
Squibb, Gilead Sciences, Human Genome Sciences, Novartis, Pharmasset, Roche/Genentech, Santaris, Schering-Plough/Merck, Tibotec and Vertex
Pharmaceuticals. None of the aforementioned commercial grant/research support was used for this specific study. Telaprevir was used in this study and is a
drug that was co-developed by Vertex and Johnson. There are no other patents, products in development, or other marketed products to declare. This doesn o t
alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: tara_kieffer@vrtx.com
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34372Introduction
The hepatitis C virus (HCV) NS3N4A protease is essential for
viral replication, and compounds that inhibit this enzyme
represent a new class of direct acting antivirals that have been
recently approved for the treatment of HCV infection [1–5].
Telaprevir (TVR, T) is a specific, reversible, covalent, tight- and
slow-binding NS3N4A protease inhibitor [6,7]. Results from
telaprevir Phase 3 trials showed that sustained virologic response
(SVR) rates were significantly higher with a regimen of 12 weeks of
telaprevir in combination with either 24 or 48 weeks of
peginterferon (P) and ribavirin (R) (PR), than with 48 weeks of
PR alone [8,9]. This increase in SVR rates was observed across a
broad range of patient populations, including treatment-naı ¨ve
patients (ADVANCE and ILLUMINATE trials) and all categories
of PR-treatment-experienced patients: prior relapsers, partial, and
null responders (REALIZE trial). However, in patients not
responding to T/PR treatment, selection of HCV variants with
decreased sensitivity to telaprevir can be observed [8–11], similar
to other direct-acting antivirals.
HCV has higher sequence diversity, even within an individual
genotype, compared with other common chronic viral infections,
such as hepatitis B virus (HBV) or human immunodeficiency virus
(HIV) [12]. This vast genetic diversity results from the high rate of
HCV replication (with up to a trillion virions produced each day)
[13] and the error-prone nature of the HCV RNA-dependent
RNA polymerase (with one mutation introduced, on average, into
every new genome) [14]. Indeed, it has been estimated that in an
HCV-infected patient, variants with every possible single and
double point mutation and even some triple mutations are created
at least once each day [15], some of which exhibit varying degrees
of resistance to protease inhibitors. However, these mutations may
have decreased replicative fitness compared with wild-type virus,
and therefore would only be present at low levels. Thus, naturally
occurring protease inhibitor-resistant variants with 2 or fewer
mutations are assumed to be present before treatment in all
patients, and can be selected in patients with suboptimal response
to treatment.
The long-term clinical implications of treatment-selected HCV
variants with reduced sensitivity to telaprevir have not been
established. Unlike HIV or HBV, which are both chronic
infections with long-lasting nuclear DNA forms capable of
archiving resistant mutations [16,17], HCV is an RNA virus that
can be eliminated and has an exclusively cytoplasmic lifecycle
[18]. Therefore, no long-lived reservoir of HCV is expected, nor
has one been demonstrated, allowing for the loss of less fit variants
from the viral population. The rate of this loss depends on several
factors, including the composition of the viral quasispecies at the
time of failure and the relative fitness of the viral population
containing the resistant variants. Even though in vitro data and
early clinical observations have shown that telaprevir-resistant
variants have a fitness disadvantage in the absence of telaprevir
[10], the ability and time-frame of the viral population to return to
the pre-treatment state have not been previously described.
To better understand the impact of protease inhibitor treatment
on the dynamic nature of the HCV population, we analyzed viral
sequences from individual patients enrolled in telaprevir clinical
trials before treatment, to define the baseline prevalence of resistant
variants, and during treatment in patients who failed to achieve an
SVR, to define the relationship between treatment failure and
emergence of resistant variants. Further analyses were performed in
patients after treatment to evaluate the evolution of resistant
variants in the absence of drug selective pressure. These analyses
provided an understanding of factors involved in the selection of
resistant variants in patients treated with telaprevir, and have been
important inoptimizing telaprevirtreatmentregimensbyincreasing
SVR rates and minimizing clinical resistance.
Methods
Ethics Statement
Studies were conducted in full compliance with the guidelines of
Good Clinical Practice and of the World Medical Assembly
Declaration of Helsinki. Prior to study initiation, protocols and
informed consent forms were reviewed and approved by
institutional review boards at each site (see Appendix). All patients
provided written informed consent before participating in any
study-related activity.
Patient Population
This study included treatment-naı ¨ve and treatment-experienced
patients who had chronic genotype 1 HCV infection and were
enrolled in Phase 2 [19–23] and Phase 3 clinical studies of
telaprevir [8,9,24]. In Phase 3 clinical trials, all patients received 8
or 12 weeks of telaprevir-based treatment followed by an
additional PR phase for a total treatment duration of either 24
or 48 weeks as determined by response-guided design. Treatment-
experienced patients were categorized by their previous response
to PR therapy: null responders, partial responders, or relapsers.
Null responders exhibited a reduction of less than 2 log10 in HCV
RNA after 12 weeks of PR therapy. Partial responders exhibited a
reduction in 2 log10 or more in HCV RNA after 12 weeks of PR
therapy but never achieved undetectable HCV RNA. Relapsers
exhibited undetectable HCV RNA at the end of a previous course
of PR therapy with detectable HCV RNA thereafter. Where
indicated, null responders and partial responders were collectively
referred to as non-responders. Further details on the study designs
can be found in Jacobson et al., 2011 (ClinicalTrials.gov number
NCT00627926); Zeuzem et al., 2011 (NCT00703118), and
Sherman et al., 2011 (NCT00758043).
Clinical virology studies were performed in the subset of patients
who had not achieved an SVR to help elucidate the reason for and
consequence of treatment failure. Treatment failure was catego-
rized as either on-treatment virologic failure or relapse.
Definition of Treatment Outcomes
In patients who did not achieve an SVR, treatment outcomes
were categorized as on-treatment virologic failure, relapse, or
other. On-treatment virologic failure included patients who met a
protocol-defined virologic stopping rule or patients with viral
breakthrough. Viral breakthrough was defined as a confirmed on-
treatment increase in HCV RNA levels of 1-log10 above nadir, or
greater than 100 IU/mL in patients who previously had
undetectable HCV RNA or HCV RNA levels below 25 IU/mL
(for Study C208 and REALIZE). On-treatment virologic failure
was further categorized based on its occurrence during the
telaprevir combination treatment phase versus the PR treatment
phase. Relapse was calculated based on the number of patients
with HCV RNA below 25 IU/mL at the end of planned
treatment followed by HCV RNA levels above or equal to
25 IU/mL after the end of planned treatment. Patients with
missing SVR assessment and patients with HCV RNA.25 IU/
mL but no viral breakthrough at planned end of treatment were
categorized as ‘‘other’’.
HCV RNA Quantitation and Subtyping
Plasma HCV RNA levels were determined using the Roche
COBAS TaqManH HCV/HPS assay (Version 2.0) for Phase 3
HCV Evolution in Telaprevir Clinical Trials
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Results below the LLOQ were reported as ‘‘,25, target detected’’
(or ,25 detectable HCV RNA), or ‘‘,25, target not detected’’ (or
undetectable HCV RNA). HCV genotype/subtype was deter-
mined by sequence analysis of the HCV NS3N4A region.
HCV RNA Sequencing
Population sequence analysis (sensitivity ,20%) of the NS3N4A
region was performed for samples with HCV RNA levels above
the limit of detection (LOD) of the sequencing assay (1000 IU/
mL) at baseline, and in patients who did not achieve SVR.
Sequencing methods have been presented elsewhere [25]. Briefly,
a blood sample was collected from patients by venipuncture of a
forearm vein into tubes containing EDTA (K2) anticoagulant.
Plasma was separated by centrifugation, aliquoted, and stored at
280uC. Sequence analysis of HCV utilized nested reverse-
transcriptase polymerase chain reaction (RT-PCR) amplification
of an approximately 9 kb HCV RNA fragment spanning the
HCV polyprotein coding region. The resulting DNA was purified
using the QIAquick 96 PCR Purification kit (Qiagen) and
analyzed on an agarose gel. Purified DNA was sent to Beckman
Coulter (AgencourtH Biosciences, Danvers, MA) for sequencing of
the NS3N4A protease region. Sequencing was successful for .95%
of attempted samples.
Sequence Analysis
Sequences were aligned and analyzed for the presence of
substitutions in the NS3N4A region using the software Mutation
Surveyor (SoftGenetics, State College, PA). Potential resistance
substitutions in the NS3N4A protease were identified using
statistical analyses. This analysis utilized pooled sequencing data
from all available patients who did not achieve an SVR with a
telaprevir-based regimen in all Phase 2 and 3 studies. Briefly, the
frequency of variants observed in the NS3N4A protease after
treatment-failure was compared statistically against the expected
frequency (derived from the pre-treatment time point). For the
comparison, the time point considered representative of the
treatment failure was the time of last dose of telaprevir after
meeting criteria for a stopping rule or viral breakthrough, end of
treatment time point, or time of relapse, where HCV RNA levels
were above the sequencing assay LOD. Significance was
calculated using either a Poisson distributed probability or a
Fisher’s exact test with a significance threshold of 0.05 (alpha)
adjusted with a Bonferroni correction. Sequencing data were
available for 521 patients with genotype 1a and 219 patients with
genotype 1b at the treatment-failure time point. This large sample
size allowed detection of significant variants even if they occurred
only rarely in the population of patients who did not achieve an
SVR with telaprevir-based treatment. In particular, D168N,
which was observed in only 6 of 521 genotype 1a patients after
treatment failure (1.15%) was still determined to be a TVR-failure
associated variant because of its extremely rare detection prior to
treatment (0.04%).
Telaprevir IC50 determination in the HCV replicon cell assay
The IC50 value of telaprevir in genotype 1b was determined in a
48-hour assay using stable HCV replicon cells as described
previously [26]. The IC50 value of telaprevir in genotype 1a was
determined in a transient replicon assay. A sub-genomic replicon
containing the G1a-H77 NS3-39 sequence with 6 adaptive
mutations (Q1067R, P1496L, V1655I, K1691R, K2040R, and
S2204I) and a luciferase gene cassette under the translational
control of the EMCV IRES and the poliovirus IRES, respectively,
was constructed. Mutations of HCV NS3 protease were
introduced into the genotype 1a replicon plasmid using PCR-
based site-directed mutagenesis. Replicon RNA was generated
from HpaI-linearized genotype 1a replicon using T7 MEGAScript
Kit (Ambion). 5 mg of replicon RNA was electroporated into Huh-
7-ET-cured cells resuspended in Ingenio (Mirus, MIR 50117).
Electroporated cells were resuspended in DMEM culture medium
and plated on 96-well plates (Costar 3904) at 1610
4 cells in 100 ml.
After incubation at 37uC for 24 h, the cell culture was added with
100 ml of medium containing compound with serial dilutions and
allowed to grow for 3 days. The cells were lysed with cell lysis
buffer (Promega E153A) and the luciferase activity was measured
with the Luciferase kit (Promega E1501) using the Envision reader.
The IC50 values were generated from dose-response curves with
SoftMax Pro.
Multiple independent assays were conducted for each viral
variant, and the mean and standard deviation (SD) of the replicon
IC50 values were calculated. The fold change in sensitivity to
telaprevir was calculated by dividing the mean IC50 for each
variant by the mean IC50 for the wild type replicon. The range of
assay variability for IC50 values is within 3-fold.
Results
Treatment Outcome in Patients from Phase 3 Telaprevir
Studies
The addition of telaprevir to PR treatment significantly increased
SVR rates compared to PR alone. In the treatment-naı ¨ve
population (ADVANCE), 12 weeks of telaprevir response-guided
combination treatment with either 24 or 48 weeks of PR resulted in
a 79% SVR rate, compared with 46% in the placebo (Pbo)/PR
group (P,0.0001) [1]. In the treatment-failure population (REAL-
IZE), 12 weeks of telaprevir in combination with 48 weeks of PR
resulted in higher SVR rates than in the Pbo/PR group: 86%
compared with 22% in prior relapsers, 59% compared with 15% in
prior partial responders, and 32% compared with 5% in prior null
responders, (P,0.001) [1]. Treatment outcomes in the intent to
treat (ITT) population were similar between treatment-naı ¨ve and
prior relapsers with low rates of on-treatment virologic failure (7%
in treatment-naı ¨ve and 1% in prior relapsers) and relapse (3% in
both treatment-naı ¨ve and prior relapsers). In contrast, SVR rates
were lower in patients with a prior non-response to PR as a result of
higher relapse rates (12%) and much higher on-treatment virologic
failure rates (38%) (Figure 1).
Resistant variants were observed in 12% (44/363) of treatment-
naı ¨ve patients (ADVANCE; T12PR arm), 6% (18/286) of prior
relapsers, and 40% (98/244) of prior non-responders {24% (23/
97) of prior partial responders and 51% (75/147) of prior null
responder patients} (REALIZE, T12PR48 arms) (Figure 2).
Regardless of treatment history, the majority of patients who did
not achieve SVR had detectable resistant variants at the time of
treatment failure (Figure 3). The proportion of non-SVR patients
with available sequence data with detectable resistant variants at
the time of failure was 79% (44/56) of treatment-naı ¨ve (T12PR,
ADVANCE), 62% (18/29) of prior PR relapsers, 61% (23/38) of
prior PR partial responders, and 81% (75/93) of prior PR null
responders (REALIZE, T12PR48 arms). In order to further
understand the reason for treatment failure, virology data were
analyzed by failure type in patients with on-treatment virologic
failure and relapse.
Resistance Profiles in Patients Who Did Not Achieve SVR
with a Telaprevir-based Regimen in Phase 2 and 3 Studies
Telaprevir-selected variants were identified from a comprehen-
sive analysis of patients who did not achieve SVR in both Phase 2
HCV Evolution in Telaprevir Clinical Trials
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were analyzed during or after treatment with telaprevir. The
analysis identified the following variants as being significantly
enriched in the population of patients who did not achieve SVR:
V36A/M, T54A/S, R155K/T, A156S/T, and D168N (Table 1).
Additionally, V36L was present at 4% after treatment failure, but
was not significantly enriched due to its frequent (1.5%)
occurrence at baseline (Table 1). Although not significantly
enriched, variants V36G/I, I132V (subtype 1a only, subtype 1b
consensus is Val at position 132), R155G/M, or A156F/N/V
were observed in less than 2% of patients who did not achieve an
SVR [1]. These variants are all included in the figures and
analyses presented here, with the exception of V36I/L and I132V
which confer less than 3-fold resistance in the replicon (see below).
The amino acid positions associated with telaprevir resistance are
located near the protease catalytic site in the NS3 protease
domain, consistent with the mechanism of action of a protease
inhibitor (Figure S1).
Figure 1. Treatment Outcome in Patients from Phase 3 Telaprevir Studies. Data from ADVANCE includes only the T12PR arm and data from
REALIZE includes pooled TVR arms. ‘Other’ includes patients with missing SVR assessment and patients with HCV RNA.25 IU/mL at last study dose
but who did not have viral breakthrough. ‘Relapse’ here is calculated using a denominator of total number of patients, and so differs from a relapse
rate calculated in Figure 8 which uses patients with undetectable HCV RNA at the end of treatment. ‘SVR’ rates here are calculated as in the INCIVEK
USPI, which utilized the last recorded HCV RNA assessment; in case of missing data, the last HCV RNA assessment from week 12 of follow-up onward
was used. For the determination of SVR and relapse rates, the lower limit of quantification (,25 IU/ml) of the HCV RNA assay was used. These rates
differ from SVR rates calculated according to the study protocol, which used the HCV RNA assessment at week 24 without carrying forward the prior
HCV RNA data point in case of missing data, and the limit of detection (10–15 IU/ml) of the HCV RNA assay for SVR and relapse rate determination.
SVR rates using the protocol analysis were: 75% for T12PR, 69% for T8PR and 44% for PR (ADVANCE, Jacobson 2011); 72%, 92% and 88% were
recorded for the overall study (all patients), T12PR24 and T12PR48 randomized arms, respectively (ILLUMINATE, Sherman 2011); and 64%, 66% and
17% for T12PR48, lead-in T12PR48 and PR, respectively (REALIZE, Zeuzem 2011).
doi:10.1371/journal.pone.0034372.g001
Figure 2. Phenotypic Resistance Profiles in Patients Who Did Not Achieve SVR with a TVR-based Regimen. Data from ADVANCE include
only the T12PR arm and data from REALIZE include pooled TVR arms. Higher-level resistance (red) is defined as .25-fold increase in IC50 and lower-
level resistance (yellow) is defined as 3- to 25-fold increase in IC50 from wild-type. Grey (n/a) indicates patients with no sequence data available due to
HCV RNA levels below the LOD of the sequencing assay or lost-to-follow-up.
doi:10.1371/journal.pone.0034372.g002
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resistance to telaprevir were observed in patients infected with
genotype 1a or genotype 1b. Overall, in patients who failed to
achieve SVR (N=388; 1a, n=269; 1b, n=119), variants observed
were wild-type (23%; V36L 2%), T54A/S (6%), V36A/M (11%),
R155K/T (10%), A156S (2%), A156T (2%), and V36M+R155K
(32%). In addition to V36M+R155K, 11% of patients had variants
with more than one substitution (Figure 3). In patients with
genotype 1a, the predominant telaprevir-resistant variants ob-
served were V36M (8%), R155K (13%), V36M+R155K (46%),
and wild-type (14%). In patients with genotype 1b, the
predominant telaprevir-resistant variants observed were V36A
(8%), T54A (18%), A156S/T/V (10%), and wild-type (44%).
Additionally, we sequenced the NS3-NS5B spanning region in
Phase 2 studies to evaluate the potential to select compensatory
mutations, and found no consistent mutations in NS3 or any of the
4 NS3N4A protease cleavage sites [27].
Characterization of Telaprevir-Resistant Variants
Phenotypic studies (enzymatic and HCV replicon-based) were
performed to characterize substitutions that had been identified in
the HCV NS3 protease domain after treatment failure in clinical
studies of telaprevir. These mutations conferred different levels of
resistance to telaprevir, ranging from a 0.3- to .62-fold increase in
IC50 from wild-type (Table 1). Variants were categorized as either
lower-level resistance, defined as a 3- to 25-fold increase in IC50
from wild-type, or higher-level, defined as more than 25-fold
increase in IC50. This distinction is clinically relevant, as nearly all
viral breakthrough during telaprevir treatment was associated with
higher-level resistant variants, indicating that telaprevir exposure
was sufficient, in combination with PR, to inhibit lower-level
resistant variants (Figure 4). A lower-level of resistance to
telaprevir was conferred by single substitutions at V36A/G/M,
T54A/S, R155G/K/M/T, and A156S. A higher-level of
resistance to telaprevir was conferred by A156F/T/V and the
double variant V36M+R155K. Variants V36I/L, I132V (subtype
1a only), and D168N did not change the sensitivity to telaprevir in
the replicon system (conferred less than 3-fold change IC50).
Telaprevir-resistant variants remained fully sensitive to interferon-
alfa, ribavirin, and representative HCV nucleoside and non-
nucleoside polymerase inhibitors in the replicon system (data not
shown). Additionally, most telaprevir-resistant variants had a lower
replication capacity than wild-type in vitro [28].
Resistance Profiles Before Telaprevir Combination
Treatment
In total, 3449 unique HCV sequences were analyzed in patients
before treatment (baseline), allowing determination of the viral
population sequence for over 98% of the patients enrolled in Phase
2 and Phase 3 clinical studies. Baseline resistance was detected by
population sequencing in 5% of patients, most of whom had either
the V36L (1.5%) or T54S (2.7%) variant, which conferred only a
2.2- or 4-fold increase in IC50 from wild-type, respectively. The
remaining patients (less than 1%) had the more clinically-relevant
V36M (0.3%), T54A (0.03%), or R155K (0.5%) mutations. All
these variants conferred lower-level resistance to telaprevir, with a
6 to 7-fold change in IC50 from wild-type replicon. The I132V
variant, which conferred a ,1-fold change in IC50 from wild-type,
was present at 0.5% of subtype 1a patients (Val is the consensus
amino acid in genotype 1b). No patient had the higher-level
resistant variants A156T or V36M+R155K.
To evaluate the impact of pre-existing telaprevir-resistant
variants on the response to a T12PR regimen in Phase 3 trials
(ADVANCE [T12 arm only], ILLUMINATE, and REALIZE),
SVR rates were compared between patients with wild-type virus at
baseline and patients with predominant variants (including V36L
and I132V) detectable by population sequencing at baseline. The
SVR rates in patients treated with T/PR were comparable, with a
70% (54/77) SVR rate for patients with variants and a 72% (964/
1337) SVR rate for patients with wild-type virus at baseline. In
treatment-naı ¨ve patients (ADVANCE and ILLUMINATE), the
SVR rate of patients with telaprevir-resistant variants at baseline
was 74% (39/53) compared with an SVR rate of 76% (634/837)
in patients who did not have a variant at baseline. In treatment-
failure patients (REALIZE), SVR rates in patients with telaprevir-
resistant variants at baseline by prior response were 14% (1/7),
Figure 3. Frequency of Resistance Profiles in Patients Who Did Not Achieve an SVR with a TVR-based Regimen. X-axis is the % of
patients with a given resistant variant out of all patients who did not achieve an SVR and had available sequence data in Phase 3 trials (n=388,
includes all TVR arms of all 3 Phase 3 trials). Higher-level resistance (red) is defined as .25-fold increase in IC50 and lower-level resistance (yellow) is
defined as 3- to 25-fold increase in IC50 from wild-type. Variants observed in only a single subject (ie, 0.26% of the failure population) are not
displayed. These variants are: V36G/I, I132V (1a), and R155M.
doi:10.1371/journal.pone.0034372.g003
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partial-responders, and prior relapsers, respectively, compared
with SVR rates of 33% (46/140), 57% (53/93), and 87% (231/
267) in patients who did not have a resistant variant at baseline.
While the overall presence of resistant variants did not appear to
affectresponse to T/PR,aneffectofindividual variantswas possible,
in particular in patients with a poor interferon response. Therefore,
the presence of the most common treatment-selected variants,
V36M and R155K, were evaluated separately. Seven of the 9
treatment-naı ¨ve patients with these variants at baseline achieved an
SVR, whereas neither of the 2 prior null responders with these
variants at baseline achieved an SVR. These results indicate that the
presence of baseline variants may impact the response to T/PR in
certain patient populations, such as prior null responders.
Resistance Profile in Patients with On-treatment Virologic
Failure
On-treatment virologic failure describes the outcome of patients
who met a virologic stopping rule or had viral breakthrough
during treatment, either during the telaprevir dosing phase or in
the subsequent PR treatment phase. In Phase 3 studies, on-
treatment virologic failure during the telaprevir treatment phase
was consistently associated with higher-level resistance in both
treatment-naı ¨ve and treatment-failure patients (Figure 5). On-
treatment virologic failure was more common with genotype 1a
and associated with the V36M+R155K variant. Even though a
consistent resistance profile was observed across patients, differ-
ences in the rate of virologic failure varied according to the
responsiveness to PR. In treatment-naı ¨ve patients (T12PR arm;
ADVANCE), the on-treatment virologic failure rate was 7% (26/
363), with 3.6% occurring during the telaprevir treatment phase
(Week 1–12) and 3.6% during the PR treatment phase. In
treatment-failure patients (T12PR48 arms; REALIZE), the on-
treatment virologic failure rate was 1% (3/286) in prior relapsers
and 38% (93/244) in prior non-responders to PR (18% in prior
partial responders and 52% in prior null responders), with 1% and
18% during the telaprevir treatment phase. On-treatment
virologic failure after telaprevir treatment, during the PR
treatment phase, was associated with either wild-type virus
Table 1. Variants of Interest from a Pooled Analysis of Subjects Who Did Not Achieve an SVR in Phase 2 and 3 Studies.
NS3 Variant
Replicon IC50 Fold-
Change
a Subtype
Treatment-Naı ¨ve Occurrence
%( n )
b
Treatment-Failure Occurrence
%( n )
c p
d
Significant
R155K 5.9 1a 1.21 (27) 71.4 (372) ,1E-307
V36M 6.8 1a 0.63 (14) 63.15 (329) ,1E-307
R155T 20.0
e 1a 0.04 (1) 3.84 (20) 8.05E-33
V36A 7.5 1a 0 (0) 2.69 (14) 6.82E-11
A156S 22.4 1a 0 (0) 1.92 (10) 5.65E-08
D168N 0.9 1a 0.04 (1) 1.15 (6) 9.52E-08
T54A 6.3 1b 0 (0) 28.31 (62) 8.55E-58
A156S 9.6 1b 0.07 (1) 10.96 (24) 3.95E-44
V36A 7.4 1b 0 (0) 16.89 (37) 7.88E-34
A156T .62
f 1b 0 (0) 7.31 (16) 1.00E-14
V36M 7.0 1b 0.07 (1) 3.65 (8) 6.60E-12
T54S 4.2 1b 2.11 (29) 7.31 (16) 2.77E-05
Observed but not significant
V36G 11.3 1b 0 (0) 0.46 (1) 1.37E-01
V36I 0.3
e 1a 0.09 (2) 0.19 (1) 3.74E-01
V36I 0.3 1b 0.29 (4) 0.91 (2) 1.34E-01
V36L 2.2
e 1a 1.89 (42) 4.03 (21) 1.32E-03
V36L 2.2 1b 0.95 (13) 2.28 (5) 6.02E-02
I132V 1.8 1a 0.54 (12) 1.54 (8) 8.35E-03
R155G 7.4
e 1a 0 (0) 0.19 (1) 1.90E-01
R155M 5.6
e 1a 0 (0) 0.19 (1) 1.90E-01
A156F .62
f 1b 0 (0) 0.46 (1) 1.37E-01
A156N .62
f 1b 0 (0) 0.91 (2) 1.88E-02
A156V .62
f 1b 0 (0) 0.46 (1) 1.37E-01
aReplicon IC50 values are the mean from at least three independent experiments with fold-change relative to wild-type (WT) replicon cells. The mean (SD) IC50 value of
telaprevir in G1b WT (mADE) replicon cells is 0.482 (0.122) mM (n=15). In G1a WT replicon the mean (SD) IC50 value of telaprevir is 0.961 (0.132) mM( n=8 ) .
bNumerator is number of subjects that possess the given variant; denominator is total count of subjects that have sequence data available at that position.
cTreatment-Failure Occurrence indicates the number of subjects in TPR or T/P containing groups from Phase 2 and 3 studies who did not achieve an SVR that had the
given variant at the treatment-failure timepoint. The denominator is the total number of subjects from Phase 2 and 3 studies who did not achieve an SVR with
treatment-failure timepoint sequencing data available.
dThe value tests for enrichment of the variant in the treatment-failure population (Alpha[Bonferroni corrected]: 1a, 0.0000919; 1b, 0.000102).
eWas determined in replicon 1b.
fThe replicon IC50 is greater than 30 mM, the maximum concentration of telaprevir used in the assay.
doi:10.1371/journal.pone.0034372.t001
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variants (Figure 6).
Resistance Profile in Patients with Relapse
Relapse was defined as the presence of detectable HCV RNA
(.25 IU/mL) during follow-up after HCV RNA,25 IU/mL at
the end of planned treatment, and was calculated using as a
denominator the number of patients with HCV RNA,25 IU/mL
at the end of treatment. In the treatment-naı ¨ve (ADVANCE,
T12PR) and prior relapser populations (REALIZE), the relapse
rates were generally low in telaprevir-containing arms: 4% (11/
298) and 3% (8/254), respectively (Figure 1). In the prior non-
responder population, relapse rates were higher for prior partial
(20%; 14/71) and prior null (24%; 15/62) responders. Relapse
rates were similar between genotypes 1a and 1b.
In patients who completed their assigned treatment regimen,
follow-up sampling was performed 4, 12 and/or 24 weeks after the
end of PR dosing. In treatment-naı ¨ve and treatment-failure
populations, relapse was associated with either wild-type virus or
lower-level telaprevir-resistant variants in most TPR treated
patients (Figure 7). Relapse rates and resistance profiles were
similar among patients who completed either 24 or 48 weeks of
treatment.
Resistance Profile in Patients Who Discontinued
Treatment Early
Patients who discontinued treatment early, prior to the planned
duration, for non-virologic reasons provided insight into changes in
the viral population under telaprevir pressure. In general, patients
who discontinued treatment early (less than 4 weeks) tended to have
predominantly wild-type virus. Elimination of the wild-type viral
population appeared to occur in most patients by 6 to 8 weeks of
treatment. In patients who received a longer treatment duration
(more than 8 weeks of telaprevir), the viral population consisted of
telaprevir-resistant variants. In ADVANCE, a 12 week telaprevir
duration had a higher SVR rate compared with 8 weeks, due to
continued telaprevir pressure on the residual wild-type and lower-
level telaprevir-resistant variants [8].
Evolution of HCV Variants After Treatment
The evolution of resistant variants was evaluated after the end of
treatment in Phase 3 studies. A conservative approach was taken
in this analysis, whereby any non-wild-type variants at positions
Figure 4. Plasma telaprevir concentration relative to the in-
vitro sensitivity of wild-type and telaprevir-resistant variants.
Telaprevir was dosed at 750 mg q8h.
doi:10.1371/journal.pone.0034372.g004
Figure 5. Frequency of Phenotypic Resistance Profiles in Patients with On-Treatment Virologic Failure during the TVR Treatment
Phase by Prior Response and Subtype in Phase 3 Studies (includes the T12/PR arm of ADVANCE and pooled TVR arms of REALIZE).
Higher-level resistance (red) is defined as .25-fold increase in IC50 and lower-level resistance (yellow) is defined as 3- to 25-fold increase in IC50 from
wild-type.
doi:10.1371/journal.pone.0034372.g005
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(genotype 1a only) and D168N. Across Phase 3 trials, population
sequencing revealed that 77% of 388 patients had a resistant
variant following treatment failure. Of the 254 patients with
resistance after treatment failure and who had additional
sequencing time points, 153 no longer had detectable resistant
variants within the median study follow-up period of 9.7 months.
Significantly, prior treatment status (naı ¨ve versus experienced)
did not affect the fraction of patients who lost resistant variants by
the end of the study follow-up (Figure 8). Among treatment-naive
patients in the T12 arm of ADVANCE, 44 patients had resistant
variants after treatment, and in 56% of these patients only wild-
type virus was detected within the follow-up observation period
(median time, 12 months). Similarly, among treatment-experi-
enced patients in REALIZE, 118 patients had resistant variants
after treatment and in 53% only wild-type virus was detected
within the follow-up observation period (median time, 9 months).
Together, this resulted in approximately 35% of non-SVR patients
Figure 6. Frequency of Phenotypic Resistance Profiles in Patients with On-Treatment Virologic Failure during the PR Treatment
Phase by Prior Response and Subtype in Phase 3 Studies (includes the T12/PR arm of ADVANCE and pooled TVR arms of REALIZE).
Higher-level resistance (red) is defined as .25-fold increase in IC50 and lower-level resistance (yellow) is defined as 3- to 25-fold increase in IC50 from
wild-type.
doi:10.1371/journal.pone.0034372.g006
Figure 7. Frequency of Phenotypic Resistance Profiles in Patients who Relapse by Prior Response and Subtype in Phase 3 Studies
(includes the T12/PR arm of ADVANCE and pooled TVR arms of REALIZE). Relapse was defined as HCV RNA.25 IU/mL during follow-up
after ,25 IU/mL at the end of planned treatment, and was calculated with a denominator of patients with undetectable HCV RNA at the end of
treatment. Higher-level resistance (red) is defined as .25-fold increase in IC50 and lower-level resistance (yellow) is defined as 3- to 25-fold increase in
IC50 from wild-type.
doi:10.1371/journal.pone.0034372.g007
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follow-up period, regardless of prior treatment status.
As reported in more detail in Sullivan et al. 2011 [29], Kaplan-
Meier (KM) estimation was used to explore the rate of loss of the
resistant variants. Interestingly, a significant difference was noted
between genotype 1a and 1b subtypes. Based on all patients failing
telaprevir combination treatment in a Phase 3 trial, the KM
estimated median (95% CI) time to wild-type after treatment
failure was 10.7 (9.6, 12.4) months in the case of 1a (N=269) and
only 0.9 (0.00, 2.10) months in the case of 1b (N=119).
Discussion
Telaprevir in combination with peginterferon and ribavirin
significantly increased sustained virologic response rates compared
with PR alone in Phase 3 studies of treatment-naı ¨ve and
treatment-experienced genotype-1 HCV patients. Genotypic and
phenotypic analyses from telaprevir clinical trials were performed
to understand the relationship between virologic failure to a
telaprevir-containing regimen and emergence of HCV variants
with decreased sensitivity to telaprevir. In Phase 3 trials, resistant
variants were observed during treatment with telaprevir in 12% of
treatment-naı ¨ve patients (ADVANCE; T12PR arm), 6% of prior
relapsers, 24% of prior partial responders, and 51% of prior null
responder patients (REALIZE, T12PR48 arms).
Clinical virology results from this extensive dataset have
established a well-characterized, consistent resistance profile for
telaprevir in genotype 1 HCV-infected patients. Lower-level
resistance to telaprevir (3- to 25-fold decrease in sensitivity) was
conferred by V36A/M, T54A/S, R155K/T, and A156S variants.
Higher-level resistance to telaprevir (over 25-fold decrease in
sensitivity) was conferred by A156T and V36M+R155K variants.
The predominant telaprevir-resistant variants observed in patients
with subtype 1a were V36M, R155K, and V36M+R155K. In
patients with subtype 1b, the predominant variants observed were
V36A, T54A, and A156S/T (Figure 3). The pathway of V36M
and R155K substitutions is not observed in subtype 1b most likely
due to the need for 2 nucleotide changes for each substitution in
this subtype compared with the need for only a single nucleotide
change in subtype 1a, but other restrictions may also exist.
Baseline Resistance
Baseline sequencing from telaprevir clinical trials suggest that
patients with naturally occurring telaprevir-resistant variants are
uncommon (detected at 2.7% for T54S, 1.5% for V36L, and ,1%
for V36M, T54A, and R155K). The clinical relevance of the
presence of these variants as a dominant quasispecies prior to
treatment remains unclear; however, their presence did not always
preclude treatment success in telaprevir clinical trials. Response
appeared to be unaffected in treatment-naı ¨ve patients, however,
the presence of baseline variants may impact the response to T/
PR in certain patient populations, such as prior null responders.
Indeed, other factors such as response to peginterferon and
ribavirin [30] as well as adherence to the treatment regimen likely
play a larger role in the response and ultimate clinical outcome to
the telaprevir treatment regimen.
Resistance Profiles in Patients Who Did Not Achieve an
SVR
The majority of patients who did not achieve an SVR had
detectable resistant variants at the time of treatment failure.
According to prior treatment history, the proportion of non-SVR
patients with detectable resistant variants at the time of failure was
79% (44/56) of treatment-naı ¨ve (T12PR, ADVANCE), 69% (20/
29) of prior PR relapsers, 61% (23/38) of prior PR partial
responders, and 81% (75/93) of prior PR null responders
(REALIZE, T12PR48 arms).
On-treatment Virologic Failure. On-treatment virologic
failure rates during the telaprevir treatment phase of the first 12
weeks of treatment were low in both treatment-naı ¨ve and prior
relapsers, and higher in prior non-responders, emphasizing the
importance of responsiveness to PR in preventing virologic failure.
Irrespective of prior response, virologic failure during the
Figure 8. Proportion of Patients with Loss of Resistant Variants after Treatment Failure during Follow-up. Of patients with available
HCV population sequence data after failing to achieve SVR, a similar fraction of treatment-naive (T12/PR arm, ADVANCE) and treatment-experienced
patients (Pooled TVR Arms, REALIZE) had resistance initially after failure. ‘After Failure’ indicates resistance profile at the visit representative of
treatment failure. ‘End of Follow-up’ indicates the end of the follow-up observation period (end of study), with a median time of 12 months (range: 0
to 17 months) in ADVANCE and 9 months in REALIZE (range: 0 to 17 months).
doi:10.1371/journal.pone.0034372.g008
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telaprevir-resistant variants, indicating that the telaprevir-based
regimen suppressed wild-type virus and lower-level variants in
most patients. Together, these data suggest that virologic failure is
primarily due to an insufficient PR response and failure of PR to
inhibit higher-level telaprevir-resistant variants. Interestingly, SVR
rates in the nonresponder population were significantly increased
by the addition of telaprevir to PR alone [31], suggesting that in
some of these patients, the responsiveness to PR which may have
been in part restored by telaprevir was sufficient to suppress the
selection of resistance. In addition, virologic failure was more
common in genotype 1a patients than in genotype 1b patients, and
was predominantly associated with the V36M+R155K variant.
This is likely because each of the two mutations in this relatively
fit, higher-level resistant variant, V36M+R155K, has a lower
genetic barrier in subtype 1a than in subtype 1b.
On-treatment virologic failure after telaprevir treatment, during
the PR treatment phase, was low in both treatment-naı ¨ve and
treatment-failure populations, and was associated with higher-level
resistant variants but also with a large number of lower-level
resistant variants and wild-type virus. These results suggest that the
12-week telaprevir-based regimen was able to suppress wild-type
and most of the resistant variants, preventing subsequent on-
treatment virologic failure during PR treatment in the majority of
patients.
Relapse. Relapse was likely due to replication of residual
virus that remained below the limit of detection at the end of
treatment. While viral sequencing at the time of relapse can
provide insight into what virus was present at the time when
treatment was stopped, because the viral population is no longer
under selective pressure it can evolve after the end of telaprevir
treatment prior to sequencing. As described further below, the
lower fitness of the resistant variants probably resulted in their loss
from the population and replacement with wild-type virus. This
process accelerated after the end of treatment as replication
increased to baseline levels. This may be one of the reasons why
relapse, and to a lesser extent virologic failure during the PR
phase, was associated with a higher percentage of lower-level
resistant variants and wild-type virus than on-treatment virologic
failure. Alternatively, it is possible that in some of these patients,
lower-level resistant variants and wild-type virus were not
completely eradicated by treatment.
Optimizing the Telaprevir/Peg-IFN/RBV Combination
Regimen to Maximize SVR
Clinical virology analyses from studies of telaprevir, peginter-
feron and ribavirin in treatment-naı ¨ve and treatment-failure
patients with genotype 1 chronic hepatitis C have provided
further insight into the optimal treatment regimen needed to
maximize response rates and minimize resistance. These results
show that in a telaprevir-based regimen, the primary role of
telaprevir is to inhibit wild-type virus and variants with lower-
levels of resistance to telaprevir (Figure 4). The complementary
role of Peg-IFN and RBV is to clear any remaining telaprevir-
resistant variants, especially higher-level telaprevir-resistant vari-
ants which pre-exist in all chronically infected patients, albeit at
low frequencies. Based on this framework, a telaprevir-based
treatment regimen should have a telaprevir dose and duration that
results in clearance of wild-type HCV and lower-level telaprevir-
resistant variants, and a PR duration sufficient to clear any
remaining variants. Clinical virology data suggest that both the
dose (750 mg q8h) and the duration (12 weeks) of telaprevir
treatment and the duration of PR treatment (24 or 48 weeks)
contribute to determining a successful treatment outcome for most
patients.
Role of Telaprevir in the Combination Regimen. Tela-
previr combination treatment resulted in a rapid elimination of wild-
type virus, predominantly driven by telaprevir. Patients who
discontinued treatment early (before 4 weeks) for non-virologic
reasons had residual virus that was predominantly wild-type,
showing that a longer duration of telaprevir treatment is required to
completely clear wild-type virus. In most patients who received longer
durations of treatment (over 8 weeks of telaprevir), the viral population
consisted predominantly of telaprevir-resistant variants. Furthermore,
in ADVANCE, the T8PR regimen resulted in a slightly higher on-
treatment virologic failure rate during the PR treatment phase (7.4%)
than in the T12PR group (3.9%); and a greater number in the T8PR
group were associated with wild-type or lower-level telaprevir-resistant
variants [8]. The increase in the proportion of lower-level telaprevir-
resistant variants suggests that the T8PR treatment provides a lower
selective pressure than the T12PR treatment, and that 8 weeks may
not be sufficient for some patients to fully clearlower-level variants and
prevent subsequent failure during PR treatment. These data show that
12 weeks of telaprevir cleared all virus in most patients, and
consistently eradicated wild-type virus in all patients. Therefore, a
telaprevir duration of 12 weeks increases the probability of SVR in
most patients.
Role of PR in the Telaprevir Combination Regimen. After
wild-type and lower-level telaprevir-resistant variants have been
eradicated and only higher-level telaprevir-resistant variants
remain, telaprevir has little further utility because of the higher-
level resistanceof the remaining variants to telaprevir. Thus, it is the
primary role of PR to eradicate these higher-level resistant variants.
Higher-level telaprevir-resistant variants have reduced fitness and
exist at a low prevalence before treatment. Although the variants
remain fully sensitive to PR treatment, patients have variable
responses to PR treatment. Thus, the duration of PR treatment will
depend on individual patient responsiveness. As a measure of
responsiveness to PR, extended rapid virologic response (eRVR),
defined as undetectable HCV RNA at 4 and 12 weeks of treatment,
wasa good predictor ofSVRafteratotalof24weeksoftreatmentin
treatment-naı ¨ve patients. The ILLUMINATE study demonstrated
non-inferiority of 24- and 48-week treatment durations in patients
achieving an eRVR [24]. In patients not achieving an eRVR or
who had a prior nonresponse to PR, a longer duration of 48 weeks
was assigned. Patients who completed the full treatment duration of
24 or 48 weeks had very low relapse rates and similar resistance
profiles of mostly wild-type or lower-level telaprevir-resistant
variants.
Evolution of Resistant Variants after Treatment. Telaprevir-
resistant variants are less fit than wild-type virus, providing a
mechanism by which variants may be replaced by wild-type virus
over time in the absence of drug-selective pressure in patients. In a
Phase 1 study of 14 day telaprevir dosing (Study 101; n=24),
wild-type virus began to reappear in some patients 10 days post-
dosing and was predominant by 3 to 7 months post-dosing in almost
all patients [10].
Sequencing results obtained after treatment from the follow-up
period of Phase 3 trials in patients who did not achieve an SVR
suggest that changes in the viral population over time favor the
replacement of telaprevir resistant variants with wild-type virus.
Kaplan-Meier modeling suggests that resistant variants were lost at
a similar rate in treatment-naı ¨ve and treatment-experienced
patients, but that resistant variants were lost significantly more
rapidly in 1b patients than in 1a patients. As reported in Sullivan
et al., this subtypic difference results from a difference in
replicative fitness in vivo between the variants commonly
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results in a median time to WT of about 10 months after treatment
failure in 1a patients as compared to only about 1 month in 1b
patients.
These results from Phase 3 studies are supported by an interim
analysis of an on-going, three-year observational study (EXTEND)
which showed that within a median follow-up time of about 2
years almost 90% (50/56) of patients no longer had resistance
detectable by population sequencing. Furthermore, a more
sensitive, clonal sequence analysis was performed in a represen-
tative subset of 20 patients who were wild-type by population
sequencing. This analysis showed that viral populations at the
follow-up time point were not significantly enriched in resistant
variants compared to baseline for each patient [31]. These results
were corroborated by another study of 13 patients from Phase 1
studies, which compared the frequency of resistant variants
determined by clonal or ultra-deep sequencing at baseline and
in a follow-up sample 4 years (on median) after treatment.
Similarly to EXTEND, all patients returned to their pre-treatment
state at the follow-up time point [32,33].
Together, these data suggest that resistant variants are
detectable by population sequencing in most patients who fail to
achieve SVR, but that their levels decline over time after
treatment, often to levels undetectable by population sequencing.
Clonal sequencing analyses further indicate that the frequency of
resistant populations eventually returns to levels similar to those
before treatment. As resistance is not likely to be genetically
archived as with HIV or HBV, it may be possible to retreat
patients with alternative treatment options, even if they include a
previously used drug or class of antiviral agents. Future studies in
patients who have failed regimens containing telaprevir or other
classes of antiviral agents will be critical in assessing this
hypothesis.
Supporting Information
Figure S1 Location of HCV NS3/4A Protease Amino
Acid Substitutions Conferring Decreased Sensitivity to
Telaprevir. Yellow ribbon represents the NS4A cofactor; blue
amino acids represent the catalytic triad of the protease.
(TIF)
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